Skip to main content

Augmenting PBGD expression in the liver as a Novel Gene therapy for Acute Intermittent Porphyria

Objectif

Acute intermittent porphyria (AIP) is a rare genetic disease in which mutations in the porphobilinogen deaminase (PBGD) gene produce insufficient activity of a protein necessary for heme synthesis. This leads to an accumulation of toxic intermediates resulting in a wide variety of problems including acute, severe abdominal pains, psychiatric and neurological disorders, and muscular weakness. Acute porphyric attacks can be life-threatening and the long-term consequences include irreversible nerve damage, liver cancer and kidney failure. AIP affects 1/10,000 people in the EU and the therapies currently available do not prevent the symptoms or consequences of acute porphyric attacks. The only curative therapy is liver transplantation and thus, new curative options are clearly needed. In 2009, the European Medicines Agency granted Orphan Drug Designation to AAV5-AAT-PBGD for the treatment of AIP. AAV is a replication-incompetent virus that has been modified to deliver genes or genetic material into human tissues or cells. AAV5-AAT-PBGD acts by delivering the PBGD expression cassette directly into hepatocytes. In heterozygous AIP patient that show 50% of the normal activity the additional PBGD activity will be sufficient to prevent the accumulation of toxic metabolites and thus, to prevent porphyric attacks. the aim of this project is the clinical development of the orphan drug AAV-AAT-PBGD for use to treat AIP. The project will be performed in three different phases. In the first phase, we will develop a GMP-compliant process to produce sufficient AAV5-AAT-PBGD for clinical trials, and we will constitute the largest possible cohorts to improve the follow-up of patients and determine the clinical criteria to select patients for gene therapy. In the second phase, the safety and efficacy of AAV5-AAT-PBGD will be explored in a dose escalation clinical phase I/II trial.

Appel à propositions

FP7-HEALTH-2010-single-stage
Voir d’autres projets de cet appel

Coordinateur

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA
Adresse
Avenida De Pio Xii 55
31008 Pamplona
Espagne

Voir sur la carte

Type d’activité
Research Organisations
Contact administratif
Andrew Solomon (Dr.)
Contribution de l’UE
€ 822 842

Participants (6)

AMSTERDAM MOLECULAR THERAPEUTICS (AMT) BV
Pays-Bas
Contribution de l’UE
€ 1 092 012
Adresse
Meibergdreef 61
1105BA Amsterdam

Voir sur la carte

Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact administratif
Tamara Tugal (Dr.)
UNIVERSIDAD DE NAVARRA
Espagne
Contribution de l’UE
€ 508 800
Adresse
Campus Universitario Edificio Central
31080 Pamplona

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Iñigo Uriarte-Pueyo (Dr.)
REGION STOCKHOLM
Suède
Contribution de l’UE
€ 70 000
Adresse
Hantverkargatan 45
104 22 Stockholm

Voir sur la carte

Type d’activité
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Contact administratif
Veronica åkers (Ms.)
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Allemagne
Contribution de l’UE
€ 321 100
Adresse
Im Neuenheimer Feld 280
69120 Heidelberg

Voir sur la carte

Type d’activité
Research Organisations
Contact administratif
Bettina Crispin (Ms.)
DIGNA BIOTECH, S.L
Espagne
Contribution de l’UE
€ 448 000
Adresse
Avenida Pio Xii 22 Officina 2
31008 Pamplona

Voir sur la carte

Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact administratif
Astrid Pañeda (Dr.)
SERVICIO MADRILENO DE SALUD
Espagne
Contribution de l’UE
€ 45 400
Adresse
Plaza Carlos Trias Bertran 7
28020 Madrid

Voir sur la carte

Type d’activité
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Contact administratif
Maria Del Mar López Martín (Ms.)